Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group

被引：0

作者：

Martin Fenner

Christoph Oing

Annette Dieing

Thomas Gauler

Karin Oechsle

Anja Lorch

Marcus Hentrich

Hans-Georg Kopp

Carsten Bokemeyer

Friedemann Honecker

机构：

[1] Hannover Medical School,Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation

[2] University Medical Center Hamburg-Eppendorf,Department of Oncology, Hematology and Bone Marrow Transplantation and Section of Pneumology

[3] Vivantes Hospital am Urban,Department of Hematology and Oncology

[4] Heinrich Heine University Medical Center Essen,Department of Radiotherapy and Radiation Oncology

[5] University Medical Center Duesseldorf,Genitourinary Medical Oncology, Department of Urology

[6] Red Cross Hospital Munich,Department of Internal Medicine III, Hematology and Oncology

[7] University Medical Center Tuebingen,Department of Oncology, Hematology, Clinical Immunology, Rheumatology and Pulmonology

[8] Robert-Bosch-Centrum für Tumorerkrankungen,Department of Molecular Oncology and Pneumological Oncology

[9] Robert-Bosch Hospital,undefined

[10] ZeTuP Tumor and Breast Center,undefined

[11] DataCite,undefined

来源：

Journal of Cancer Research and Clinical Oncology | 2019年 / 145卷

关键词：

Germ cell cancer; Testicular cancer; mTOR; Everolimus; Refractory; Cisplatin resistance;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：717 / 723

页数：6

共 50 条

[31] An open-label, single-center, phase II, single-arm trial of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma
Xie, Y.
Mi, L.
Zheng, W.
Ping, L.
Lin, N.
Tu, M.
Zhang, C.
Ying, Z.
Liu, W.
Deng, L.
Wu, M.
Wang, X.
Zhu, J.
Song, Y.
ANNALS OF ONCOLOGY, 2020, 31 : S652 - S652
[32] Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer:: A study of the German Testicular Cancer Study Group
Kollmannsberger, C
Rick, O
Derigs, HG
Schleucher, N
Schöffski, P
Beyer, J
Schoch, R
Sayer, HG
Gerl, A
Kuczyk, M
Spott, C
Kanz, L
Bokemeyer, C
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (08) : 2031 - 2037
[33] A single-arm, phase II study of durvalumab (D) and tremelimumab (T) for relapsed/ refractory germ cell tumors (GCT)
Funt, Samuel A.
Knezevic, Andrea
Freeman, Benjamin A.
Bolos, Mary
Martorana, Victoria
Donoghue, Mark
Khan, Shah
Singh, Harleen
Bromberg, Maria
Quinlan, Colleen
Carousso, Maryann
Jungbluth, Achim A.
Patil, Sujata
Shah, Neil J.
Lee, Chung-Han
McHugh, Deaglan Joseph
Al-Ahmadie, Hikmat A.
Feldman, Darren R.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[34] Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study
Oechsle, K.
Honecker, F.
Cheng, T.
Mayer, F.
Czaykowski, P.
Winquist, E.
Wood, L.
Fenner, M.
Glaesener, S.
Hartmann, J. T.
Chi, K.
Bokemeyer, C.
Kollmannsberger, C.
ANNALS OF ONCOLOGY, 2011, 22 (12) : 2654 - 2660
[35] Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: A prospective randomized multicenter trial of the German Testicular Cancer Study Group
Lorch, Anja
Kollmannsberger, Christian
Hartmann, Joerg Thomas
Metzner, Bernd
Schmidt-Wolf, Ingo G. H.
Berdel, Wolfgang E.
Weissinger, Florian
Schleicher, Jan
Egerer, Gerlinde
Haas, Antje
Schirren, Rebekka
Beyer, Joerg
Bokemeyer, Carsten
Rick, Oliver
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (19) : 2778 - 2784
[36] An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma
Izutsu, Koji
Makita, Shinichi
Nosaka, Kisato
Yoshimitsu, Makoto
Utsunomiya, Atae
Kusumoto, Shigeru
Morishima, Satoko
Tsukasaki, Kunihiro
Kawamata, Toyotaka
Ono, Takaaki
Rai, Shinya
Katsuya, Hiroo
Ishikawa, Jun
Yamada, Hironori
Kato, Kazunobu
Tachibana, Masaya
Kakurai, Yasuyuki
Adachi, Nobuaki
Tobinai, Kensei
Yonekura, Kentaro
Ishitsuka, Kenji
BLOOD, 2023, 141 (10) : 1159 - 1168
[37] A Multicenter, Open-Label, Single-Arm, Phase Ib Clinical Trial of HH2853 in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphoma
Hong, Huangming
Zhang, Mingzhi
Peng, Zhigang
Shen, Jianzhen
Shuang, Yuerong
Zhou, Hui
Guo, Hongqiang
Huang, He
Li, Fei
Qian, Zhengzi
Liu, Lihong
Wang, Liang
Yang, Wei
Zhang, Liling
He, Pengcheng
Qian, Shen
Li, Fugen
Li, Meng
Lin, Tongyu
BLOOD, 2023, 142
[38] TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer
D. Ferraro
D. Goldstein
R. L. O’Connell
J. R. Zalcberg
K. M. Sjoquist
N. C. Tebbutt
P. Grimison
S. McLachlan
L. L. Lipton
P. Vasey
V. J. Gebski
C. Aiken
M. Cronk
S. Ng
C. S. Karapetis
J. Shannon
Cancer Chemotherapy and Pharmacology, 2016, 78 : 361 - 367
[39] TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer
Ferraro, D.
Goldstein, D.
O'Connell, R. L.
Zalcberg, J. R.
Sjoquist, K. M.
Tebbutt, N. C.
Grimison, P.
McLachlan, S.
Lipton, L. L.
Vasey, P.
Gebski, V. J.
Aiken, C.
Cronk, M.
Ng, S.
Karapetis, C. S.
Shannon, J.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (02) : 361 - 367
[40] A Phase II, Multicenter, Single-Arm, Open-Label Study of Parsaclisib, a PI3Kd Inhibitor, in Relapsed or Refractory Follicular Lymphoma in China
Zheng, Zhong
Zhang, Huilai
Wang, Jingwen
Zhou, Keshu
Zhang, Li
Zhou, Hui
Zhang, Qingyuan
Zhao, Weili
BLOOD, 2021, 138

← 1 2 3 4 5 →